Shanghai, China
Biotree is a leading mass-spectro research service provider in ACPC, offering multiomics services. Since its establishment in 2013, the company has rapidly grown and now stands as one of the largest in its field. As of 2023, Biotree has catered to over 2000 research institution clients with its metabolomics and proteomics services, establishing a strong reputation and client base.
With its headquarters in China, Biotree recently secured a Series A investment on 03 January 2023. The investors in this round include Qiming Venture Partners, KingMed Diagnostics, and Kejin Holdings. This funding round is indicative of the growing interest and support from the investment community, solidifying Biotree's position in the market and providing resources for further expansion and innovation.
As the company continues to thrive in the enterprise sector, its recent investment and partnerships signal a promising trajectory. With a strong foundation and a clear focus on cutting-edge research services, Biotree is well-positioned to capitalize on the growing demand for its multiomics services and make significant strides in the industry.
